Enclomiphene for Low Testosterone: A Fertility-Preserving Option

For men with low testosterone who want to maintain fertility, traditional testosterone replacement therapy (TRT) presents a significant dilemma: exogenous testosterone suppresses the body's own production and can dramatically reduce sperm count. Enclomiphene — a selective estrogen receptor modulator (SERM) — has emerged as a promising alternative that may raise testosterone levels while preserving fertility. Here's what the evidence shows.

What Is Enclomiphene?

Enclomiphene is the trans-isomer of clomiphene citrate, a medication that has been used in fertility medicine for decades. Standard clomiphene citrate (Clomid) is a mixture of two isomers: enclomiphene (the active estrogen-blocking component) and zuclomiphene (which has estrogenic properties and a longer half-life). Enclomiphene isolates the beneficial anti-estrogenic isomer, which may offer a cleaner pharmacological profile.

While clomiphene citrate is FDA-approved for female ovulatory dysfunction, enclomiphene is currently used off-label for male hypogonadism. It has been studied in clinical trials and was previously being developed under the brand name Androxal, though it has not yet received FDA approval as a standalone product.

How Enclomiphene Works

Enclomiphene works by blocking estrogen receptors in the hypothalamus and pituitary gland. Normally, estrogen (produced from testosterone via aromatization) provides negative feedback that suppresses the release of gonadotropin-releasing hormone (GnRH), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). By blocking this feedback loop, enclomiphene stimulates the body to produce more LH and FSH, which in turn signal the testes to produce more testosterone and maintain sperm production.

This is fundamentally different from TRT, which provides exogenous testosterone and shuts down the hypothalamic-pituitary-gonadal (HPG) axis. With TRT, LH and FSH levels drop near zero, and sperm production can decrease by 90% or more. Enclomiphene, by contrast, works with the body's natural hormone signaling rather than replacing it.

Clinical Evidence

Several clinical trials have evaluated enclomiphene for secondary hypogonadism in men:

Phase II and III trials (published in The Journal of Clinical Endocrinology & Metabolism and other journals) demonstrated that enclomiphene at doses of 12.5–25 mg daily significantly increased total testosterone, LH, and FSH levels compared to placebo. Importantly, sperm concentration was maintained or improved in enclomiphene-treated men — a stark contrast to the suppression seen with testosterone therapy.

A 2014 study comparing enclomiphene to topical testosterone gel found that both treatments raised testosterone to similar levels, but enclomiphene maintained normal sperm counts while the testosterone gel group experienced significant decreases. Another trial demonstrated sustained testosterone elevation over 12 months of treatment with an acceptable safety profile.

Key Findings

• Enclomiphene raised testosterone levels to the normal range (typically 400–700 ng/dL) in most study participants with secondary hypogonadism
• Sperm parameters (count, motility) were preserved or improved
• LH and FSH levels increased, confirming the mechanism of action
• The effect was reversible — testosterone and gonadotropin levels returned to baseline after discontinuation

Enclomiphene vs. Traditional TRT

Understanding the tradeoffs between these approaches is essential:

• Fertility preservation: Enclomiphene's primary advantage. TRT suppresses spermatogenesis; enclomiphene supports it.
• Testosterone levels: TRT can achieve very specific target levels. Enclomiphene raises testosterone through natural pathways, so the degree of increase depends on testicular function.
• Symptom relief: Some men report that TRT provides more robust symptom relief (energy, libido, body composition). Enclomiphene may produce more modest symptomatic improvements, though this varies individually.
• Primary vs. secondary hypogonadism: Enclomiphene works best for secondary hypogonadism (pituitary/hypothalamic origin). In primary hypogonadism (testicular failure), the testes may not respond adequately to increased LH stimulation.

Dosing and Administration

In clinical trials, enclomiphene has been studied at doses of 12.5 mg and 25 mg daily, taken orally. The appropriate dose depends on baseline testosterone levels, response to treatment, and individual factors determined by a licensed provider. Regular lab monitoring — including testosterone, LH, FSH, estradiol, and CBC — is important during treatment.

Because enclomiphene is currently used off-label, it may be obtained through compounding pharmacies when prescribed by a licensed provider. Availability and formulations may vary.

Side Effects and Safety

Enclomiphene has generally been well-tolerated in clinical trials. Reported side effects include headache, nausea, dizziness, and hot flashes — similar to the side effect profile of clomiphene citrate. Unlike standard clomiphene, enclomiphene's absence of the zuclomiphene isomer may reduce the risk of visual disturbances and estrogenic side effects, though more data is needed to confirm this advantage.

Potential concerns include elevated estradiol levels (since increased testosterone production also increases aromatization substrate), which may require monitoring. Some providers may consider low-dose aromatase inhibitors if estradiol becomes significantly elevated, though this adds complexity to the treatment protocol.

Who Is a Good Candidate for Enclomiphene?

Enclomiphene may be most appropriate for men with secondary hypogonadism who wish to preserve fertility (current or future), younger men with low testosterone who are not ready to commit to lifelong TRT, men who want to avoid testicular atrophy associated with exogenous testosterone, and those who prefer stimulating natural testosterone production over replacement.

It may be less suitable for men with primary hypogonadism (where testes cannot respond to increased signaling), men who need rapid or very high testosterone levels for severe symptoms, and those who have not had a thorough evaluation to determine the cause of low testosterone.

The Bottom Line

Enclomiphene represents an important option in the treatment of male hypogonadism, particularly for men who prioritize fertility preservation. While it may not provide the same magnitude of testosterone increase or symptom relief as traditional TRT in all cases, its ability to maintain sperm production makes it a valuable tool in a licensed provider's treatment toolkit.

The decision between enclomiphene, TRT, or other interventions should be made in consultation with a licensed provider who can evaluate your specific hormonal profile, symptoms, fertility goals, and overall health.

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any treatment.